
JPMorgan says own this drug stock. It’s one Jim Cramer is itching to buy again newsthirst.
JPMorgan touts Bristol Myers Squibb as a top biopharma pick. Jim Cramer is also quite fond of it. The news In a Friday note, JPMorgan analysts said Bristol Myers is well positioned to “further re-rate” as Cobenfy goes wider. The oral drug designed to help treat adults with schizophrenia has the potential to reach peak…